Figure 1. Evaluation and Diagnosis of Study Participants for Hereditary Transthyretin Amyloid Cardiomyopathy.

Across both studies, there were 9694 individuals of African or Hispanic/Latino ancestry entered into the primary analysis. Of these, there were 237 TTR V122I variant carriers, 92 of whom had confirmed heart failure based on clinical criteria after physician medical review. Only 10 of the 92 TTR V122I carriers with heart failure had been clinically evaluated for and diagnosed as having cardiac amyloidosis.

^aCriteria for quality control were not mutually exclusive and therefore the numbers do not sum to the total number of unique individuals failing quality control.